Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got a bunch of news today, from the rejection of a closely watched drug to the Trump administration’s autism announcements.

Contamination at Novo manufacturing facility trips up a biotech’s drug approval — again

Scholar Rock said this morning that the FDA rejected its treatment for the muscle-wasting disease spinal muscular atrophy due to long-unresolved problems at a contract manufacturing facility where the drug is packaged.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page